Price$0.38+0.03 (+8.40%)
01:30 PM07:45 PM
News · 26 weeks53+333%
2025-10-262026-04-19
Mix2590d
- Market9(36%)
- Other8(32%)
- Insider3(12%)
- SEC Filings3(12%)
- Leadership2(8%)
Latest news
25 items- SECAmendment: SEC Form S-3/A filed by Cosmos Health Inc.S-3/A - Cosmos Health Inc. (0001474167) (Filer)
- NEWSCosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated ProductsScience-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meetThree products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic support, and inflammation & mobility across three of the fastest-growing health categories in the U.S.Institutional-grade scientific standard: Patented ingredients, published randomized controlled trials, exact clinical dosing - built to the standard of institutional science, not mark
- NEWSCosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product PortfolioPhase 1 complete: product development, packaging, and initial commercial setup finalized ahead of scheduleProduction commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk$5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross marginsDirect-to-consumer model: scalable DTC strategy with targeted advertising and disciplined capital allocationEarly U.S. traction confirmed: commercial indicators from existing products shaping revenue expectations and go-to-market strategy CHICAGO, IL / ACCESS Newswire / April 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM),
- NEWSCosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint HealthClinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts.Derived predominantly from turmeric (~98.5%), maintaining a composition closer to the natural profile of the plant.Utilizes a turmeric-derived ingredient described as self-affirmed GRAS and evaluated in published research showing up to 39× higher free curcumin bioavailability under study conditions. CHICAGO, IL / ACCESS Newswire / April 17, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the planned Q2 2026 U.S. market launch of Cur18™, a next-generation curcum
- NEWSCosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the continued integration of artificial intelligence (AI) across its operations, reflecting ongoing investments aimed at enhancing efficiency, reducing costs, improving customer experience, and driving sales growth.AI is becoming an increasingly important component of Cosmos Health's operating model and a key enabler across multiple areas of its business, with initial efficiency gains already being realised. In certain areas, the Company believes that AI-driven optimisation may reduce specific opera
- SECCosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cosmos Health Inc. (0001474167) (Filer)
- SECSEC Form 10-K filed by Cosmos Health Inc.10-K - Cosmos Health Inc. (0001474167) (Filer)
- NEWSCosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core SegmentsScaled contract manufacturing division, securing long-term agreements for over 12 million unitsExpanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders for over 300,000 units across new marketsAdvanced R&D pipeline, securing patented anticancer drugs, multiple AI-driven patent filings, and CCX0722 weight management product entering final developmentSecured $300 million financing facility to launch digital asset treasury strategyCEO Greg Siokas increased ownership by over 3.3 million shares, reinforcing deep insider convictionStrong momentum continues into 2026 with record growth across all core segments and continued U.S. expansion underwayCHI
- NEWSCosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million UnitsCHICAGO, IL / ACCESS Newswire / April 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has received a new purchase order for 60,000 units of its Sky Premium Life products from Pharmalink under the existing exclusive distribution agreement for the United Arab Emirates (UAE) market. This marks the third consecutive purchase order from Pharmalink, bringing cumulative orders to 270,000 units since the partnership's inception in June 2024.Sustained and Growing UAE DemandThis latest order follows a clear pattern of accelerating demand in the UAE market. In June 2024, Cosmos Health s
- NEWSCosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 MonthsCHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company's operations, supply chain, or business performance. The Company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track.Geopolitical Resilience Underpins Global PlatformCosmos Health operates through a diversified international platform spanning Europe, North America, and other key regions.
- NEWSCosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat ReductionPowered by BergacynFF®, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials.CHICAGO, IL / ACCESS Newswire / April 8, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the planned Q2 2026 U.S. launch of Liv18™, a next-generation liver health supplement powered by BergacynFF®, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials.The Liver Fat Epidemic: $7+ Bi
- NEWSCosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical MarketsCHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that C-Scrub Wash 4%, manufactured by its wholly owned subsidiary Cana Laboratories S.A., has successfully completed testing under EN 12791:2016+A1:2017, the European standard for surgical hand disinfection.The independent study, conducted by Quality Assurance & Control Systems Ltd. (QACS), a Greece-based testing and certification laboratory specializing in microbiological and disinfectant efficacy studies, confirmed that C-Scrub Wash 4% demonstrated effective antimicrobial activity for surgical hand
- SECSEC Form NT 10-K filed by Cosmos Health Inc.NT 10-K - Cosmos Health Inc. (0001474167) (Filer)
- PRCosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated TransactionsContinues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization
- PRCosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of Bitcoin as part of its ongoing digital assets treasury initiative. Following this purchase, Cosmos Health's total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum. Greg Siokas, CEO of Cosmos Health, stated: "We continue to view select digital assets as an attractive asset class with strong upside potential. Our growing position in Bitcoin and Ethereum reflects a disciplined treasury strategy design
- PRCosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent ("LOI"), through its wholly owned subsidiary CosmoFarm S.A. ("CosmoFarm"), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026. The network currently generates approximately €10 million (approximately $11.5 million based on the prevailing EUR/USD exchange rate) in annual gross reve
- PRCosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory BoardCHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun
- PRCosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book ValueCHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value. Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company's Cana Laboratories ("Cana") manufacturing facility and CosmoFarm logistics center at approximately $15 million. This estimate reflects the value of the land and buildings only and excludes t
- PRCosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health RetailerCHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% ("C-Scrub"), is now available through Superdrug, the UK's second-largest beauty and health retailer. Established over 60 years ago, Superdrug is widely recognized for its leadership in health, wellness, and personal care categories and operates more than 830 stores across the UK and the Republic of Ireland, including over 200 in-store pharmacies and a growing number of healt
- PRCosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK's Largest RetailerCHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% ("C-Scrub"), is now available through Tesco, the UK's largest retailer. Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailers globally, generating over $80 billion in annual revenue. In the UK, Tesco is the clear market leader, holding nearly 30% market share and serving millions of customers weekly through
- PRCosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its participation in World Health Expo Dubai 2026 (formerly Arab Health), one of the world's largest and most influential healthcare exhibitions and conferences. The Expo was held February 9–12, 2026, at the Dubai Exhibition Centre in Expo City Dubai, United Arab Emirates, where Cosmos Health exhibited at Booth SA.A79. The event, which accommodates more than 235,000 visitors and over 4,300 exhibitors from more than 180 countries, brings together healthcare leaders, distributors, manufacturers, and i
- INSIDERChief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- INSIDERChief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)
- PRCosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select CryptocurrenciesCHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company's disciplined, opportunistic, and flexible approach to capital deployment. The Company's digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pillar of the program, the addition of Bitcoin represents a strategic evolution intended to broaden exposure across established digital assets. Cosmos Health is also selectively evaluati
- INSIDERChief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)4 - Cosmos Health Inc. (0001474167) (Issuer)